(877) 410-8172
Home  »  Investor Alerts  »  Proteoform (Allumiqs) Investment Losses

Proteoform (Allumiqs) Investment Losses

Date:

October 21, 2025

Type of alert:

Unsuitable Recommendations  

Investors have reported losses after purchasing shares of Proteoform Scientific, a Canadian biomedical research company now known as Allumiqs Corporation. A lawsuit filed by the attorneys at ChapmanAlbin and Kuglar Law alleges that certain investment professionals recommended unsuitable and speculative pre-IPO investments in Proteoform and similar high-risk startup ventures.

According to the lawsuit, brokers pressured clients to invest by promoting the company as a groundbreaking opportunity with massive upside potential while downplaying the risks inherent in early-stage biotech investments. As with many pre-IPO startups, investors in Proteoform/Allumiqs have suffered significant financial losses.

If your accountant, investment advisor, or stockbroker recommended an investment in Proteoform Scientific or Allumiqs Corporation, you may be able to recover your losses.

Contact the attorneys at ChapmanAlbin to discuss your potential recovery options at (877) 410-8172

Contact Us If You Believe You Have a Case

"*" indicates required fields

Name*

Please note: We are unable to take cases with losses of less than $50,000.

Consent*
This field is for validation purposes and should be left unchanged.

(877) 410-8172

© 2025 ChapmanAlbin

This site contains attorney advertising. The attorneys at ChapmanAlbin are licensed to practice law in Ohio and Michigan. Any reference to past cases or successes made herein should not be construed as a guarantee of any future outcome. Each client and each client’s case is unique, and no result or outcome is or can ever be guaranteed. The information provided in this website is offered for general information purposes only; it is not offered as and does not constitute legal advice in any way. // Disclaimer